IVERIC bio $324.7 million stock offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $324.7 million SEC-registered offering by IVERIC bio, Inc. of 15,352,500 shares of common stock, including the full exercise by the underwriters of their option to purchase 2,002,500 additional shares of common stock. IVERIC’s common stock is listed on the Nasdaq Global Select Market under the symbol “ISEE.”
IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration.
The Davis Polk corporate team included partner Roshni Banker Cariello and associates Michael Schuster and Robert MacKenzie. The tax team included partner Ethan R. Goldman and associate Dov Sussman. Partner Pritesh P. Shah provided intellectual property advice. All members of the Davis Polk team are based in the New York office.